AIFM2 and cancer: Moreover, bioinformatic analyses of people with cancer harboring T327M mutations in FSP1 (Extended Data Fig. 6b)25 suggest that certain individuals might be resistant to treatment with FSP1 inhibitors, thus likely necessitating personalized treatment approaches.